Secondary analysis of the IELSG37 trial: in 495 patients with primary mediastinal B-cell lymphoma given rituximab- and doxorubicin-based immunochemotherapy, high baseline PET metabolic heterogeneity was linked to 5-year PFS of 65% vs 93% with low (OS 80% vs 96%).
Secondary analysisn = 501
Ceriani et al. Metabolic heterogeneity-based radiomic model predicts treatment outcomes of primary mediastinal B-cell lymphoma patients in the IELSG37 study